Pharma Foods International Co., Ltd. (JP:2929)
:2929
Want to see JP:2929 full AI Analyst Report?
Top Page
Pharma Foods International Co., Ltd.
(2929)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥547.00
▼(-19.44% Downside)
Action:Reiterated
Date:06/11/26
The score is held back primarily by weak cash flow and sharply lower profitability, reinforced by bearish technicals with the stock trading well below key moving averages. A strong dividend yield and improved leverage provide partial support, but do not outweigh the cash-generation and momentum risks.
Positive Factors
Consistent revenue growth
Sustained revenue growth indicates continued product demand and market traction for wellness and functional-ingredient offerings. Over 2–6 months this supports scale benefits, predictable top-line for planning, and the ability to fund product development and distribution expansion without relying solely on financing.
Negative Factors
Negative operating and free cash flow
Negative operating and free cash flow signal the business is not converting revenue into sustainable cash, forcing reliance on financing or asset sales to fund operations and dividends. This weak cash generation is a structural risk to reinvestment, product launches, and balance sheet resilience over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained revenue growth indicates continued product demand and market traction for wellness and functional-ingredient offerings. Over 2–6 months this supports scale benefits, predictable top-line for planning, and the ability to fund product development and distribution expansion without relying solely on financing.
Read all positive factors
Pharma Foods International Co., Ltd. (2929) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥15.79B
Dividend Yield3.65%
Average Volume (3M)110.46K
Price to Earnings (P/E)36.9
Beta (1Y)0.81
Revenue Growth8.42%
EPS Growth49.52%
CountryJP
Employees642
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.72
Shares Outstanding29,079,000
10 Day Avg. Volume122,950
30 Day Avg. Volume110,460
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)2.21
Price to Sales (P/S)0.39
P/FCF Ratio-12.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharma Foods International Co., Ltd. Business Overview & Revenue Model
Company Description
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a ...
How the Company Makes Money
null...
Pharma Foods International Co., Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.00B | 65.26B | 62.15B | 68.57B | 60.19B | 46.75B |
| Gross Profit | 54.02B | 52.53B | 48.65B | 55.21B | 48.06B | 39.68B |
| EBITDA | 1.91B | 3.15B | 6.02B | 4.16B | 1.60B | 5.86B |
| Net Income | 430.00M | 368.00M | 3.21B | 3.08B | -374.00M | 3.84B |
Balance Sheet | ||||||
| Total Assets | 34.86B | 32.78B | 36.57B | 36.23B | 31.16B | 20.94B |
| Cash, Cash Equivalents and Short-Term Investments | 8.77B | 9.16B | 15.67B | 16.31B | 8.85B | 9.79B |
| Total Debt | 17.21B | 12.66B | 16.90B | 20.12B | 16.89B | 4.92B |
| Total Liabilities | 24.77B | 21.23B | 24.99B | 26.60B | 24.08B | 12.48B |
| Stockholders Equity | 10.08B | 11.55B | 11.59B | 9.63B | 7.07B | 8.46B |
Cash Flow | ||||||
| Free Cash Flow | -4.54B | -1.98B | 4.54B | 5.74B | -6.53B | 5.78B |
| Operating Cash Flow | -3.67B | -1.09B | 5.49B | 6.13B | -6.07B | 5.94B |
| Investing Cash Flow | -951.00M | -950.00M | -1.39B | -1.01B | -2.54B | -442.00M |
| Financing Cash Flow | 3.03B | -4.47B | -4.84B | 2.34B | 7.68B | 1.03B |
Pharma Foods International Co., Ltd. Technical Analysis
Negative
679.00
Price Trends
630.24
Negative
641.38
Negative
709.65
Negative
Market Momentum
-28.55
Positive
37.50
Neutral
39.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Negative. The current price of 679 is above the 20-day moving average (MA) of 590.00, above the 50-day MA of 630.24, and below the 200-day MA of 709.65, indicating a bearish trend. The MACD of -28.55 indicates Positive momentum. The RSI at 37.50 is Neutral, neither overbought nor oversold. The STOCH value of 39.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2929.
Pharma Foods International Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥284.30B | 10.06 | 9.05% | 3.30% | 6.36% | -11.73% | |
63 Neutral | ¥8.76B | 14.02 | ― | 2.55% | -0.61% | 14.58% | |
53 Neutral | ¥8.89B | 39.08 | ― | 1.06% | 27.18% | 252.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥15.79B | 36.89 | ― | 3.65% | 8.42% | 49.52% | |
50 Neutral | ¥5.60B | 28.67 | ― | 3.21% | 1.60% | -32.57% |
* Healthcare Sector Average
JP:2929
Pharma Foods International Co., Ltd.
543.00
-283.97
-34.34%
JP:4540
Tsumura & Co
3,790.00
567.03
17.59%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
256.00
-49.43
-16.18%
JP:4524
Morishita Jintan Co., Ltd.
2,150.00
97.87
4.77%
JP:4539
Nippon Chemiphar Co., Ltd.
1,571.00
123.19
8.51%
Pharma Foods International Co., Ltd. Corporate Events
Pharma Foods Details FY2026 Q3 Results and Medium-Term Plan Progress
Jun 10, 2026
Pharma Foods International Co., Ltd. released supplementary materials outlining its consolidated financial results for the third quarter of FY2026/7. The company also presented its consolidated earnings forecast and reported on the progress of its...
Pharma Foods Posts Nine-Month Loss but Maintains Dividend and Confirms Profit Recovery Forecast
Jun 10, 2026
Pharma Foods International reported consolidated net sales of ¥48.6 billion for the nine months ended April 30, 2026, up 3.7% year on year, but posted an operating loss of ¥1.43 billion and a net loss attributable to owners of the parent...
Pharma Foods Lifts FY2026 Forecast as Upfront Investments Boost Profitability
Mar 23, 2026
Pharma Foods International reported that the first half of FY2026 was an aggressive investment phase, with strategic upfront spending executed as planned to strengthen its business base and future profitability. The company is redefining its ̶...
Pharma Foods Swings to Interim Loss but Signals Full-Year Profit Rebound
Mar 13, 2026
Pharma Foods International reported consolidated net sales of ¥32.44 billion for the six months ended January 31, 2026, up 8.7% year on year, but swung to an operating loss of ¥2.36 billion and a net loss attributable to owners of the pa...
Pharma Foods Raises Profit Outlook for FY2026 on Strong B2C and New Products
Mar 13, 2026
Pharma Foods International has revised its full-year consolidated forecast for the fiscal year ending July 2026, projecting slightly lower net sales of JPY 67 billion but significantly higher profitability. The company now expects operating and or...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.